SecBot SecBot
PRESS-RELEASE ·Filed Mar 18, 2026

XOMA

XOMA Royalty Corporation
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Traders should monitor upcoming 2026 catalysts, particularly EMA decisions on OJEMDA and MIPLYFFA and Phase 3 data for ersodetug, which could drive further royalty upside. The company’s shift to positive operating cash flow and active buybacks support shareholder value, but litigation risk with Janssen remains a watch item.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$27.35
T+0 close · Mar 18, 2026 · via day close
Latest settled
+52.83%
T+60 · $41.80
Vs SPY
+41.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $27.35entry
  2. T+1 · 8mo ago +5.16%α +5.42% · $28.76
  3. T+5 · 8mo ago +10.42%α +11.14% · $30.20
  4. T+20 · 7mo ago +44.83%α +38.78% · $39.61
  5. T+60 · 5mo ago +52.83%α +41.31% · $41.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

XOMA Royalty Corporation reported strong full-year 2025 financial results with revenue up 83% YoY to $52.1 million and a swing to net income of $31.7 million from a $13.8 million loss in 2024, driven by higher royalty and milestone receipts. The company repurchased $16.0 million in shares and expanded its portfolio with 22 new assets and seven acquisitions, while also securing potential future upside from late-stage pipeline catalysts in 2026.

Key Financial Metrics

Revenue
$52.1M
+82.7% YoY
Adj. EPS
$1.46
GAAP: $1.53
Deal Value
$852.6M

Key Facts

  • Full-year 2025 revenue: $52.1 million (up 83% YoY from $28.5 million)
  • Net income: $31.7 million in 2025 vs. net loss of $13.8 million in 2024
  • Achieved $50.5 million in cash receipts: $33.6 million in royalties, $16.9 million in milestones
  • Repurchased and retired 648,048 shares for $16.0 million in 2025
  • Completed seven acquisitions, adding $11.7 million in non-dilutive capital and exposure to up to $1.1 billion in potential milestones
  • Takeda deal expansion: up to $852.6 million in potential milestones and low to mid-single-digit royalties on nine assets
  • Key 2026 catalysts: Phase 3 data for ersodetug in tumor HI, EMA decisions on OJEMDA and MIPLYFFA, and Phase 2b data for volixibat in PSC

Financial Impact

Revenue increased by $23.6 million YoY, with net income improving by $45.5 million. Operating cash flow turned positive at $2.9 million in 2025 vs. -$13.7 million in 2024.

revenuenet incomecash flowdilutioneps

Risk Factors

  • Clinical setbacks in key pipeline assets (e.g., ersodetug failed to meet statistical significance in congenital HI)
  • Ongoing litigation with Janssen Biotech with uncertain outcome and potential for continued legal costs
  • Dependence on third-party drug development success and regulatory approvals

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257974

Track record

8 reports on XOMA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jul 27, 202616w ago 15-12G Bearish 7/10 No price data
  2. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $40.17 to $40.17 · 0.00% +0.47% vs SPY
  3. Jun 12, 202622w ago DEFA14A Bullish 8/10 Entry $41.95 to $42.00 ▲ +0.12% +1.50% vs SPY
  4. Jun 12, 202622w ago 8-K Neutral 4/10 Entry $41.95 to $42.00 ▲ +0.12% +1.50% vs SPY
  5. Mar 18, 202634w ago Press Release Neutral 3/10 Entry $28.76 to $30.53 ▲ +6.15% +8.37% vs SPY
  6. Mar 18, 202634w ago 8-K Neutral 4/10 Entry $27.35 to $30.20 ▲ +10.42% +11.14% vs SPY
  7. Mar 18, 202634w ago Press Release Bullish 8/10 Viewing Entry $27.35 to $30.20 ▲ +10.42% +11.14% vs SPY
  8. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $26.86 to $28.76 ▲ +7.07% +8.05% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 18, 2026